These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 9006809

  • 1. Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats.
    Krause BR, Barnett BC, Essenburg AD, Kieft KA, Auerbach BJ, Bousley R, Stanfield R, Newton RS, Bisgaier CL.
    Atherosclerosis; 1996 Nov 15; 127(1):91-101. PubMed ID: 9006809
    [Abstract] [Full Text] [Related]

  • 2. Effect of gemfibrozil on triacylglycerol synthesis and secretion by liver and lipoprotein lipase activity in adipose tissue of rats.
    Nagao K, Sakono M, Nakayama M, Hirakawa T, Imaizumi K.
    Comp Biochem Physiol B Biochem Mol Biol; 1999 Nov 15; 124(3):289-94. PubMed ID: 10631806
    [Abstract] [Full Text] [Related]

  • 3. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR, Newton RS.
    Atherosclerosis; 1995 Oct 15; 117(2):237-44. PubMed ID: 8801869
    [Abstract] [Full Text] [Related]

  • 4. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor.
    Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, Leff T, White AD, Creger P, Pape ME, Rea TJ, Newton RS.
    J Lipid Res; 1998 Jan 15; 39(1):17-30. PubMed ID: 9469582
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
    Chen MF, Wang TD, Yeh HT, Hsu HC, Lee YT.
    Eur J Clin Invest; 2001 Aug 15; 31(8):707-13. PubMed ID: 11473572
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 Aug 15; 11(3):331-40. PubMed ID: 2743372
    [Abstract] [Full Text] [Related]

  • 9. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May 15; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of action of gemfibrozil on lipoprotein metabolism.
    Saku K, Gartside PS, Hynd BA, Kashyap ML.
    J Clin Invest; 1985 May 15; 75(5):1702-12. PubMed ID: 3923042
    [Abstract] [Full Text] [Related]

  • 11. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
    Brisson D, Ledoux K, Bossé Y, St-Pierre J, Julien P, Perron P, Hudson TJ, Vohl MC, Gaudet D.
    Pharmacogenetics; 2002 Jun 15; 12(4):313-20. PubMed ID: 12042669
    [Abstract] [Full Text] [Related]

  • 12. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
    Haubenwallner S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T.
    J Lipid Res; 1995 Dec 15; 36(12):2541-51. PubMed ID: 8847480
    [Abstract] [Full Text] [Related]

  • 13. Fibrates and triglyceride metabolism.
    Schwandt P.
    Eur J Clin Pharmacol; 1991 Dec 15; 40 Suppl 1():S41-3. PubMed ID: 2044642
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
    Norioka M, Suzuki M, Ryomoto K, Ikebuchi M, Harano Y.
    J Atheroscler Thromb; 2000 Dec 15; 7(4):198-202. PubMed ID: 11521682
    [Abstract] [Full Text] [Related]

  • 16. Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.
    Maxwell RE, Nawrocki JW, Uhlendorf PD.
    Atherosclerosis; 1983 Sep 15; 48(3):195-203. PubMed ID: 6579963
    [Abstract] [Full Text] [Related]

  • 17. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients.
    Dachet C, Cavallero E, Martin C, Girardot G, Jacotot B.
    Atherosclerosis; 1995 Feb 15; 113(1):1-9. PubMed ID: 7755644
    [Abstract] [Full Text] [Related]

  • 18. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L, Szostak WB.
    Eur J Clin Pharmacol; 1991 Feb 15; 40(1):33-41. PubMed ID: 2060543
    [Abstract] [Full Text] [Related]

  • 19. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats.
    Krause BR, Newton RS.
    J Lipid Res; 1985 Aug 15; 26(8):940-9. PubMed ID: 3862732
    [Abstract] [Full Text] [Related]

  • 20. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
    Nakandakare E, Garcia RC, Rocha JC, Sperotto G, Oliveira HC, Quintão EC.
    Atherosclerosis; 1990 Dec 15; 85(2-3):211-7. PubMed ID: 2102085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.